Drug Type Small molecule drug |
Synonyms HDM1002/SGLT-2i, HDM1002/SGLT2 inhibitor, HDM-1010 |
Target |
Action agonists, inhibitors |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Molecular FormulaC33H35FN4O5 |
InChIKeySFKAXUUDIGSMBK-SANMLTNESA-N |
CAS Registry2886728-09-0 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | IND Approval | United States | 06 Jun 2025 | |
| Diabetic Nephropathies | Preclinical | China | 24 Mar 2026 |





